Hannah Berner’s 11-Week Smile Update: Before and After Her Dysport Reaction
Comedian and podcaster Hannah Berner spent nearly three months unable to pull the corners of her mouth upward. What began as a routine neuromodulator session intended to relieve chronic jaw tension quickly turned into an unexpected public case study in cosmetic complications. According to an initial People.com Report, Berner took to social media to reveal that an off-label injection designed to ease her temporomandibular joint (TMJ) pain had inadvertently immobilized her lower facial expressions.
Eleven weeks after the botched treatment, Berner shared a candid video update displaying her gradual recovery. The clip provided concrete visual proof that her facial symmetry was returning, offering relief to her millions of followers while sparking renewed scrutiny of masseter neurotoxin injections across commercial medspas.
📌 Quick Summary:
- The Incident: Hannah Berner received Dysport in her masseter muscles to relieve TMJ pain, but the neurotoxin migrated into the adjacent risorius muscle, freezing her ability to smile.
- The Recovery Marker: At 11 weeks post-procedure, video evidence confirmed approximately 80% to 90% restoration of voluntary mouth corner elevation as the toxin metabolized.
- The Clinical Cause: Off-target neurotoxin diffusion happens when injections are placed too superficially, too far anteriorly, or in doses that spread beyond the masseter border.
The TMJ Treatment That Froze Hannah Berner's Expression
Berner sought treatment for severe teeth grinding and jaw clenching. The standard medical intervention for severe TMJ pain often involves injecting botulinum toxin type A, sold under brand names like Botox, Dysport, or Xeomin, directly into the masseter muscles. By weakening these thick chewing muscles, injectors can alleviate tension headaches, reduce dental wear, and soften an overly square jawline.
The procedure turned catastrophic within days. In early July 2026, Berner published clips revealing that while her jaw tension had decreased, her lower face refused to move when she laughed. Instead of widening and elevating, her lips remained pinned in a rigid, horizontal grimace. The physical reaction immediately disrupted her stand-up performances and live tapings, forcing her to explain her frozen expression to audiences before delivering punchlines.
Neuromodulators work by blocking the release of acetylcholine at the neuromuscular junction. When injected precisely into the deep belly of the masseter, the chemical paralysis remains isolated to mastication. If the toxin drifts forward by even a few millimeters, it encounters the delicate mimetic muscles responsible for authentic human emotion.
The 11-Week Smile Update: Visual Signs of Recovery
On September 2, 2026, Berner posted an 11-week milestone video tracking her facial mobility. In the visual update, she demonstrated her capacity to recruit the zygomaticus major and risorius muscles once again. The corners of her mouth lifted symmetrically, and the unnatural flattening of her midface had visibly diminished.
The recovery process was slow and entirely organic. Because there is no clinical antidote or dissolving agent for botulinum neurotoxins, Berner had to wait for her nerve terminals to sprout new unblocked junctions. Her update showed roughly 85% normal kinetic range, with subtle residual weakness on the right side during forced laughter.
Her community reacted with collective relief. Comments poured in across TikTok and Instagram from patients who had suffered identical cosmetic mishaps and felt isolated by the medical gaslighting common in commercial aesthetics. Berner used her signature irreverence to normalize the ordeal, framing the 11-week video as tangible proof that neuromodulator-induced paresis is almost always temporary.
Tracking the Timeline from Injection to Nerve Recovery
The trajectory of neurotoxin-induced facial paralysis follows a predictable pharmacological curve. Unlike dermal fillers, which can be dissolved instantly with hyaluronidase enzymes, neurotoxins must clear via systemic cellular turnover.
| Recovery Stage | Timeframe | Clinical Presentation | Berner’s Public Record |
|---|---|---|---|
| Initial Paralysis | Days 4, 14 | Toxin diffuses to risorius; complete loss of lateral mouth pull | Discloses frozen smile on social media; TMJ pain reduced |
| Peak Immobility | Weeks 2, 6 | Maximum chemical blockade; zero voluntary corner retraction | Jokes on Giggly Squad about looking like a ventriloquist doll |
| Initial Sprouting | Weeks 7, 10 | Axonal sprouting begins; slight twitching and partial lift return | Notes subtle improvements during live stand-up dates |
| Functional Restoration | Weeks 11, 16 | Reinnervation of risorius; return of natural smile dynamics | Releases 11-week video update verifying dynamic smile recovery |
The Risorius Muscle Dilemma: Why Masseter Dysport Migrates
The anatomy of the lower face leaves zero margin for clinical error. The masseter is a massive, thick muscle positioned deep beneath layers of fascia. Resting immediately superficial and anterior to it sits the risorius, a thin, highly variable ribbon of muscle that tethers the corner of the mouth to the cheek tissue.
Dysport (abobotulinumtoxinA) has distinct molecular characteristics compared to Botox (onabotulinumtoxinA). Clinical literature demonstrates that Dysport features a slightly wider halo of diffusion due to differences in protein complexes and diluent volumes. When an injector inserts the needle too close to the anterior border of the masseter, or fails to inject deeply enough into the muscle belly, the neurotoxin seeps through the fascia into the risorius.
The result is instant functional paresis. The patient tries to laugh, but the zygomaticus pulls upward while the deadened risorius fails to pull outward. This creates an unnatural, snarl-like deformity. Studies in aesthetic surgery indicate this specific complication occurs in 2% to 5% of masseter injections, making it the most frequent adverse event associated with jawline contouring.
The Giggly Squad Reaction and Medspa Accountability
Rather than retreating from the public eye, Berner turned the botch into high-performing comedic content. In late August 2026, she told E! News that she had found an unexpected upside to the incident: it provided an endless stream of organic material for her hit podcast, Giggly Squad, which she co-hosts with Paige DeSorbo.
On September 9, 2026, Berner doubled down on the satire in a follow-up interview with People.com, joking that she needed a "top-off" from the very medspa that paralyzed her smile because the resulting press coverage had been so lucrative for her career. Her co-host DeSorbo spent entire episodes breaking down the visual absurdity of Berner attempting to deliver emotional punchlines with an immobile face.
Underneath the self-deprecating comedy sits a severe regulatory problem. The rapid expansion of franchised medspas has democratized neurotoxins at the cost of clinical rigor. Many high-volume clinics employ injectors who complete weekend certification courses without deep anatomical training in facial planes, increasing the risk of preventable diffusion errors.
Navigating Masseter Injections: Patient Protocols and Red Flags
Patients seeking masseter treatments for either bruxism or aesthetic jaw slimming must approach the procedure as a specialized medical intervention rather than a casual spa service. The margin between therapeutic jaw relief and three months of lower-face paralysis comes down to millimeter precision.
Ideal Clinical Candidates:
- Individuals with verified severe bruxism diagnosed by a dentist or maxillofacial specialist.
- Patients with prominent masseter hypertrophy confirmed via dynamic clenching palpation.
- Those treated exclusively by board-certified dermatologists, plastic surgeons, or specialized dental surgeons.
High-Risk Profiles and Red Flags:
- Injectors who do not palpate the anterior border of the masseter to draw safety boundary lines.
- Clinics offering bargain unit pricing that relies on heavy dilution volumes, which increases drug migration.
- Patients with pre-existing midface laxity, where masseter reduction can cause premature cheek sagging.
- Anyone receiving injections without aspiration checks or strict post-care instructions prohibiting lying down or strenuous exercise for 6 hours.
Frequently Asked Questions (FAQ)
Why did Hannah Berner’s smile freeze after getting Dysport?
The Dysport injected into her masseter muscle migrated anteriorly and superficially, hitting the risorius muscle. The risorius pulls the lips outward and horizontally during a smile; once paralyzed, her mouth corners could not retract normally.
Can you reverse a botched masseter Dysport or Botox injection?
No. Unlike hyaluronic acid dermal fillers, botulinum neurotoxins cannot be broken down with an enzyme. Patients must wait for their bodies to metabolize the toxin and grow new nerve terminal connections, a process that typically requires 10 to 16 weeks.
Is Dysport riskier than Botox for TMJ jaw slimming?
Dysport is not inherently dangerous, but it possesses a larger diffusion radius than Botox due to its protein profile. Injectors must account for this wider spread by placing injections further back from the anterior masseter border and using concentrated reconstitution volumes.
The Evolving Landscape of Neuromodulators in 2026
Hannah Berner’s transparent documentation of her 11-week recovery stripped away the glossy, consequence-free marketing surrounding modern cosmetic procedures. Her viral updates turned an embarrassing clinical side effect into an essential educational moment for millions of casual medspa consumers.
Off-label masseter injections will continue to surge as TMJ issues rise from chronic stress and screen-time clenching. However, Berner's experience proves that even minor miscalculations carry tangible functional costs. True safety in aesthetic medicine relies not on clever marketing, but on deep anatomical expertise and an uncompromised respect for the delicate mechanics of the human face.
